To say that Big Pharma is corrupt is an understatement, especially after a shocking new study published in the British Medical Journal found that drug makers actually purchase positive field trial results so that it will be easier, cheaper and quicker to get new drugs approved.
As reported by The Daily Sheeple, financial ties between researchers and Big Pharma firms “are independently associated with positive trial results, suggesting bias in the evidence base,” according to the new study.
For their study, which was published in the BMJ, researchers analyzed results from 195 drug trials that were reported in 2013. Led by experts from the University of California-San Francisco, the research team discovered that in more than half of clinical trials – 58 percent – the lead scientist in the study had at least some level of financial ties to the company that made the drug under testing. (RELATED: Keep current with the most recent medical scandals at Medicine.news)
Included in the cozy relationships were direct payments to researchers, honorariums, paid travel expenses, stock ownership and payment for "advisory" work.
In an accompanying editorial, entitled, The Ties That Bind, the BMJ noted:
"Substantial evidence shows that sponsorship or funding of trials of drugs and devices by companies producing the drug or device results in publications that tend to favour the sponsor’s product. Personal financial ties—including travel expenses, honorariums, payment for advisory work, or stock ownership—between commercial companies and authors of reviews, meta-analyses, editorials, and letters are also associated with conclusions favourable to the sponsor."
The fraudulent nature of clinical trials involving Big Pharma has been known to insiders for quite some time, including Dr. Marcia Angell, a physician and longtime Editor in Chief of the New England Medical Journal.
“It is simply no longer possible to believe much of the clinical research that is published, or to rely on the judgment of trusted physicians or authoritative medical guidelines. I take no pleasure in this conclusion, which I reached slowly and reluctantly over my two decades as an editor of The New England Journal of Medicine,” she has said.
Natural News founder/editor Mike Adams, the Health Ranger, has also tracked the issue of faking drug trial results so that pharmaceutical firms can get their flawed products to market faster.
“There's no question whatsoever that the bulk of drug company-funded clinical trials are rooted in scientific fraud,” he said. “Much of the entire body of so-called 'scientific evidence' cited by the FDA to justify the granting of prescription drug monopolies is nothing more than pharmaceutical voodoo and quackery disguised to look like legitimate science.” (RELATED: The most recent discoveries can be found at Scientific.news)
In a separate news release, Andreas Lundh of the University of Southern Denmark, and Lisa Bero of the University of Sydney, said that more studies, and more transparency, are needed for clinical trials:
"They urge trial authors to share their data and participate in industry funded trials only if data are made publicly available - and suggest journals could help by rejecting research by authors who are unwilling to share their data and by penalising authors who fail to disclose financial ties. The role of sponsors, or companies with which authors have ties, in the research must also be transparent," EurkAlert reported.
President Trump has vowed to clean out the cesspool that is Big Pharma’s power lock in the nation’s capital.
“Pharma has a lot of lobbyists and a lot of power,” he said during his first press conference as president-elect recently. “There’s very little bidding on drugs. We’re the largest drug buyer in the world, and we’re going to start bidding. We’re going to start saving billions of dollars on drugs.”
In addition to implementing a bidding process and making other changes to how Big Pharma does business, Trump is considering appointing vaccine skeptic, Robert F. Kennedy, Jr., to a special panel to look into their safety.
J.D. Heyes is a senior writer for Natural News and News Target, as well as editor of The National Sentinel.
Sources:
Please contact us for more information.
